Immunocore Holdings Plc Sponsored ADR IMCR 深 滬
等待開盤 07-18 09:30:00 美东时间
36.21
+0.465
+1.30%
華盛通- 最 高36.36
- 今 開35.56
- 成交量 12.01万股
- 最 低 35.30
- 昨 收 35.745
- 總市值 18.19亿
- 52周最高 40.5175
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 23.15
- 委 比 -16.96%
- 總股本 5023.36万
- 歷史最高 76.98
- 量 比 0.49
- 振 幅 2.97%
- 歷史最低 18.43
- 每 手 1
- 風險率 13.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Immutep Limited announces positive initial data from its Phase I study of IMP761, a novel LAG-3 agonist antibody for autoimmune diseases. Results show significant T cell suppression and a favorable safety profile at the 0.9 mg/kg dose level. IMP761 has the potential to silence dysregulated T cells, offering a targeted approach with fewer side effects. The study will continue with higher single ascending doses of 2.5, 7, and 14 mg/kg, with additio...
06-23 12:00
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
During the last three months, 9 analysts shared their evaluations of Immunocore...
06-03 05:00
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
Immunocore's management will participate in the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 11:05 a.m. EDT. The event will be available via webcast on Immunocore's investor webpage and replayed for limited time. Immunocore is a biotech company developing innovative TCR bispecific immunotherapies for cancer, autoimmune diseases, and infectious diseases. Their lead oncology product, KIMMTRAK, has been approved in multiple region...
06-02 11:00
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Results from the Phase 1b trial of IMA203 PRAME cell therapy in 33 heavily pretreated metastatic melanoma patients show favorable tolerability and durable clinical activity, with a confirmed ORR of 56%, mDOR of 12.1 months, mPFS of 6.1 months, and mOS of 15.9 months. Subgroup analyses demonstrate strong responses in both cutaneous (cORR 50%) and uveal melanoma (cORR 67%). These findings support the ongoing SUPRAME Phase 3 trial and highlight Imma...
05-31 12:00
Immuron Letter to Shareholders: Projects Update
Immuron Limited reported record sales of $7 million for FY2025, up from $4.9 million last year. Key updates include: Travelan® clinical study results expected in October 2025; IMM-529 IND submission to FDA in August 2025 forClostridioides difficile infection; ProIBS® launch in Australia planned for January 2026; and IMM-986 pre-clinical results anticipated in August 2025 for Vancomycin-resistant enterococci. Sales momentum continued through Easte...
05-30 10:00
Oppenheimer Maintains Outperform on Immunocore Holdings, Raises Price Target to $86
Oppenheimer analyst Jeff Jones maintains Immunocore Holdings (NASDAQ:IMCR) with a Outperform and raises the price target from $85 to $86.
05-08 22:28
Immunocore Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.
Immunocore Holdings shares are trading higher after the company reported better...
05-08 00:24
Immunocore Hldgs Q1 GAAP EPS $0.10 Beats $(0.39) Estimate, Sales $93.88M Beat $88.52M Estimate
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.39) by 125.64 percent. This is a 120.41 percent increase over losses of $(0.49) per share
05-07 21:36
美股大行评级 | 潜在涨幅684.71%！Verve Therapeutics获Canaccord Genuity升目标价至39美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Verve Therapeutics(VERV)"买入"评级，目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.：维持Verve Ther
04-16 09:45
